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Abstract.
Most existing theoretical models of photodynamic therapy (PDT) assume a uniform
initial distribution of the photosensitive molecule, Protoporphyrin IX (PpIX). This is
an adequate assumption when the prodrug is systematically administered; however for
topical PDT this is no longer a valid assumption. Topical application and subsequent
diffusion of the prodrug results in an inhomogeneous distribution of PpIX, especially
after short incubation times, prior to light illumination. In this work a theoretical
simulation of PDT where the PpIX distribution depends on the incubation time
and the treatment modality is described. Three steps of the PpIX production are
considered. The first is the distribution of the topically applied prodrug, the second
in the conversion from the prodrug to PpIX and the third is the light distribution
which affects the PpIX distribution through photobleaching. The light distribution is
modelled using a Monte Carlo radiation transfer model and indicates treatment depths
of around 2 mm during daylight PDT and approximately 3 mm during conventional
PDT. The results suggest that treatment depths are not only limited by the light
penetration but also by the PpIX distribution.
1. Introduction
Photodynamic therapy (PDT) is a non-invasive light based therapy used for treating
superficial skin lesions such as Aktinic Keratosis (AK) and Basal Cell Carcinoma (BCC).
The combination of light, a photosensitive molecule and oxygen results in selective
tissue destruction through the production of singlet oxygen (Wilson and Patterson,
2008). The photosensitive molecule Protoporphyrin IX (PpIX) is produced as a result
of a topically applied prodrug, which diffuses into the skin. For topically applied
PDT it is common to use precursors to the photosensitive molecule Porotporphyrin
IX (PpIX) such as the naturally occurring amino acid 5-Aminolevulinenic acid (ALA)
2or its methyl ester methyl aminolevulinate (MAL). The distribution of this prodrug and
thereby the concentration of PpIX will depend on the distance from the surface and
the total time since application. For topical PDT it is therefore important to include
this inhomogeneous distribution (in the vertical plane) of the photosensitiser (Svaasand
et al., 1996; van den Akker et al., 2000). This results in a more accurate dosimetry model
compared to when the initial distribution of PpIX is assumed to be uniform (Campbell
et al., 2015).
When choosing an appropriate light source for PDT there are several aspects
to consider. Firstly, the wavelengths have to match the absorption bands of the
photosensitiser so that a sufficient amount of singlet oxygen is produced. The
illumination area has to be sufficient to treat the selected region and the irradiation has
to be high enough to provide a good treatment response, whereas the irradiance has to be
low enough to reduce the experienced pain. A typical light source used for conventional
PDT is the Akilite (Photocure ASA, Hoffsveien, N-0377 Oslo, Norway) which is a red
LED based light source (Moseley, 2005). This treatment modality is typically associated
with pain during light illumination (Castano et al., 2004). An alternative treatment
modality is daylight PDT, where daylight is used as the alternative therapeutic light
source. This has been shown to result in a high response rate, a reduced experienced
pain and the preferred choice of treatment from the patient’s point of view (Wiegell
et al., 2008, 2012, 2013, 2011). In the work presented here both conventional PDT as
well as daylight PDT are considered.
During conventional PDT, the prodrug (containing either ALA or MAL) is topically
administered to the lesion 3 hours before the light illumination. During this occlusive
treatment phase, the prodrug diffuses through the skin and is subsequently converted
within the mitochondria of the tumour cells to the photosensitive chemical PpIX
(Wachowska et al., 2011; Donnelly et al., 2007; Aalders et al., 2001; Donnelly et al.,
2005). For daylight PDT however this occlusive treatment phase is typically (only) 30
minutes (Morton et al., 2015).
To our knowledge there have been no theoretical investigations of PDT which
takes into consideration these different treatment modalities. This paper introduces a
Monte Carlo radiation transfer (MCRT) model of PDT where the temporal and spatial
dependence of the PpIX production is considered. Previous studies have considered
topical application of the prodrug to theoretically determine the distribution of the
PpIX after the occlusive treatment phase. These different studies have used slightly
different approaches (Svaasand et al., 1996; Star et al., 2002; Salas-Garc´ıa et al., 2012;
Salas-Garc´ıa et al., 2014). The study by Star et al included the most complicated
conversion model between the prodrug and the PpIX, however a maximum penetration
depth of 0.5 mm was assumed. This contradicts other studies where a deeper penetration
is indicated (Casas et al., 2000; Donnelly et al., 2007; Malik et al., 1995; Juzenas et al.,
2009; Naghavi et al., 2011).
By combining both the PpIX production model with the MCRT model both light
penetration limitations and drug penetration limitations can be explored. This results
3in more appropriate representation of PDT for the different treatment conditions. The
developed model invites discussion regarding the appropriateness of the length of the
occlusive treatment phases and the effect of prolonged daylight exposure.
2. Methods
The production of PpIX as a result of topical administration of a prodrug is a complex
procedure with multiple steps. The model presented here contains what is believed to
be the most relevant parameters, thus reducing the number of required assumptions and
approximations. The model is primarily based on basic molecular diffusion theory in
combination with a simple rate equation. A one dimensional case was considered where
the concentration of PpIX was assumed to only vary in the vertical direction (from
the surface of the tissue). Firstly, the MCRT model will be described followed by an
explanation of the PpIX production model.
2.1. Monte Carlo radiation transfer modelling
MCRT modelling is a numerical technique which utilises the probabilistic nature of
the photon interactions to simulate the transport, scattering and absorption of light
within scattering media. By tracking photons through their random walk, important
information about the energy deposition and light distribution within the simulation
volume during illumination can be generated. The code that was used throughout this
work was developed from a publicly available FORTRAN code (Wood, 2013; Wood
and R. J. Reynolds, 1999) which was originally developed for astronomy applications.
The code has subsequently been adapted for simulating PDT and has been extensively
validated (Campbell et al., 2015; Valentine et al., 2011).
The code simulates the propagation of photons through a three dimensional (3D)
Cartesian grid containing 106 voxels. The dimensions of the simulation region were
10 mm×10 mm×10 mm and a cylindrical tumour region was placed in the centre of the
grid with a diameter of 6 mm and a depth of 10 mm. The simulated photons were given
an initial direction and wavelength and were launched from the surface of the grid such
that the surface was evenly illuminated. The photons were subsequently tracked until
they were either absorbed of scattered out of the simulation region. Repeated boundary
conditions were adopted to simulate a semi-infinite tissue slab.
The scattering and absorption events are determined by the optical properties
within each individual voxel. When a photon reaches an interaction location, the
probability of the photon being scattered is determined by the albedo which is defined
as,
a =
µs(λ)
µs(λ) + µa(λ)
(1)
where µs(λ) and µa(λ) corresponds to the wavelength dependent scattering and
absorption coefficients associated with the skin tissue. The optical properties of the
4skin tissue adopted in this work are the same as those used in previous work (Campbell
et al., 2015; Yudovsky and Pilon, 2011; Salomatina et al., 2006). When adding a non-
uniform distribution of PpIX, the optical absorption properties associated with the PpIX
will also be non-uniform and vary with PpIX concentration. The absorption coefficient
for PpIX will depend on the local number density of PpIX molecule such that,
µaPpIX(λ) = nPpIXσPpIX(λ) (2)
where nPpIX is the number density of PpIX molecules (cm
−3) and σPpIX(λ) is the
wavelength dependent PpIX cross section (cm2) shown in figure 1.
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Figure 1: PpIX cross section as a function of wavelength. The absorption coefficient
is generated by multiplying the cross section (displayed in the figure) with the PpIX
number density of PpIX molecules present in each voxel (Salas-Garc´ıa et al., 2012).
If the photon is scattered as a result of an interaction event the new angular
scattering direction is determined by the Henyey-Greenstein phase function (HG(θ))
(Henyey and Greenstein, 1941).
HG(θ) =
1
4pi
1− g2
(1 + g2 − 2gcosθ)3/2 (3)
where θ is the scattering angle and g is the anisotropy factor which describes the
nature of the scattering. g can take values in the range −1 ≤ g ≤ 1, where g =
0 corresponds to isotropic scattering. In skin tissue, the scattering is predominantly
forward scattering (g > 0). In the work presented here the wavelength dependent
anisotropy factor g(λ) = 0.62 + 0.29× 10−3λ (with λ in nm) was adopted (Van Gemert
5et al., 1989). The refractive index was assumed to be uinform throughout the skin
tissue (n = 1.38) and Fresnel equations were adopted to determine the reflectance and
refraction at the air/tissue interface.
2.2. Prodrug diffusion
The first step is to consider the diffusion of the prodrug since this dictates the
distribution of PpIX molecules. Molecular diffusion, where molecules diffuse from a
region of high concentration to a region of lower concentration is described by Fick’s
first law,
J = −D∂M(z, t)
∂z
(4)
where J corresponds to the flux vector which describes the flow of substance
(molecules) through a unit area per unit time (m−2s−1). The magnitude of J is
proportional to the gradient of the concentration M(z,t) (m−3). In this case, M(z,t)
corresponds to the number density of MAL molecules. D (m2 s−1 ) is the diffusivity,
or diffusion coefficient, which describes the speed at which a substance diffuses through
another substance.
By applying the continuity equation for mass conservation (Svaasand et al., 1996),
∂J
∂z
+
∂M(z, t)
∂t
= 0 (5)
and combining with equation 4, the equation that describes how M(z,t) changes
with time is,
∂M(z, t)
∂t
= D
∂2M(z, t)
∂z2
(6)
By assuming that the initial concentration, M0 is introduced at t=0 and z=0, and
thereafter kept constant at M0 the following solution satisfies equation 6 (Crank, 1975):
M(z, t) = M0(1− erf
(
z√
4Dt
)
) (7)
where the gaussian error function (erf) is defined as
erf(u) =
2√
pi
∫ u
0
e−t
2
dt (8)
This boundary condition was assumed due to the excess cream still present on
the lesion after 3 hours of occlusive treatment, acting as a reservoir and thus the
concentration of MAL (or ALA) molecules could be kept constant at the surface. Since
the diffusion problem described here can be compared to a plane source with an extended
initial distribution, the standard solution (equation 7) was believed to be an appropriate
description of the prodrug diffusion. Similar assumptions have previously been argued
for and applied in other studies where similar models were developed such as (Crank,
1975; Star et al., 2002; Svaasand et al., 1996; Salas-Garc´ıa et al., 2012; Salas-Garc´ıa
6et al., 2014). A diffusion barrier is not considered in the presented model since these
properties are to our knowledge not well characterised. It is believed that the diffusion
barrier in a tumour region is reduced compared to healthy skin (Svaasand et al., 1996).
In combination with a light curettage of the surface of the skin it is assumed, for the
purpose of this study, that the diffusion barrier does not affect the diffusion of the
cream. A reduced concentration of the prodrug at the upper part of the skin compared
to previous studies is however assumed. We acknowledge that this is an initial first
order approximation and that the concentration of prodrug at the upper part of the
skin will only reach its maximum value after some time. However, we believe that for
the purpose of this paper this assumption is sufficient. Future work should investigate
the diffusion barrier of skin further.
2.3. PpIX production
PpIX is produced from ALA molecules. In the work presented here a prodrug containing
MAL molecules was considered, however the conversion from MAL to ALA was not
separately included and only the conversion from MAL to PpIX was considered in the
equation describing the production of PpIX. The rate equation is expressed as follows
(Svaasand et al., 1996; Star et al., 2002),
∂P (z, t)
∂t
= −P (z, t)
τp
+ εp
M(z, t)
τap
(9)
Equation 9 includes the two main features that contribute to the resulting
concentration of PpIX. The source term in the equation (term furthest to the right)
corresponds to the conversion from MAL molecules to PpIX molecules. This depends
on the distribution of MAL molecules, M(z,t), the yield, εp, which determines the
proportion of MAL molecules being converted to PpIX, as well as the relaxation time,
τap. The relaxation time, τap determines how fast this conversion happens and is defined
as the time it takes for the concentration (M(z,t)) to reduce to 1/e (37 %) of its original
concentration due to PpIX production. The sink in this equation is the first term to the
right of the equal sign. This term corresponds to the clearance of the PpIX (mostly due
to heme production). The rate at which the clearance mechanism happens is dictated
by the relaxation time, τp.
The solution to equation 9 is (Svaasand et al., 1996) to be ,
P (z, t) =
εp
τap
∫ t
0
e
− t−t′
τp M(z, t′)dt′ =
M0εp
τap
∫ t
0
e
− t−t′
τp (1−erf
(
z√
4Dt′
)
)dt′(10)
To establish the resulting PpIX concentration due to the PpIX production model,
the parameters M0, εp, τap, τp and D have to be established. The parameters used for the
work presented here were taken from the literature and are summarised in table 1. The
initial cream concentration M0 was chosen such that it lies between two extremes. In
previous publications the initial uniform concentration of PpIX has been assumed to be
around 1014 cm−3 (Campbell et al., 2015), while work by Salas Garcia et al has suggested
7an initial concentration of MAL molecules to be around 1020 cm−3 (Salas-Garc´ıa et al.,
2012). For this reason a value of 6 × 1016 MAL molecules per cubic centimetre was
chosen for the present study. Even though the concentration of the cream has been
reported to be of the orders of 1020 cm−3 it is assumed that a diffusion barrier reduced
the amount of cream passing through it. Hence it is assumed that 6× 1016 cm−3 is the
concentration of MAL molecules in the top layer of the skin.
Table 1: Parameters used to determine the PpIX production
Parameter value
M0 [cm
−3] 6× 1016
εp 0.5 (Salas-Garc´ıa et al., 2012)
τap [s] 8640 (Star et al., 2002)
τp [s] 4680 (Star et al., 2002)
D [m2 s−1] 0.69× 10−10 (Salas-Garc´ıa et al., 2012; Svaasand et al., 1996)
2.4. Photobleaching
The equation described above does not include any light interaction and only considers
the production of PpIX. When PpIX interacts with light, the concentration of PpIX
molecules reduces with time due to photobleaching. This type of reduction of
concentration was considered within the MCRT model but was however not included
in the rate equation (equation 9). Therefore it was assumed that the concentration
reduction due to photobleaching did not affect the diffusion of the prodrug molecules
or the production of PpIX. The photobleaching is assumed to only depend on the
fluence rate as well as the initial PpIX concentration (Jacques et al., 1993; Farrell et al.,
1998; Robinson et al., 1998; Valentine et al., 2011; Jongen and Sterenborg, 1997). The
photobleaching adopted in the work here was expressed using the following equation,
C(x, y, z, t) = C0(x, y, z)e
−ψ(x,y,z)t/β(λ) (11)
where C(x, y, z, t) is the local time dependent PpIX concentration, C0(x, y, z)
corresponds to the distribution of PpIX which depends on equation 10 as well as the
different treatment modalities (see section 2.5). ψ(x, y, z) is the local fluence rate in
W cm−2 which is computed within the MCRT model. The wavelengths dependent
photobleaching dose constant, β(λ) is defined as,
β(λ) = β(630)
µaPpIX(630)
µaPpIX(λ)
630
λ
(12)
Here µaPpIX(630) is the absorption coefficient of PpIX at 630 nm and β(630) is
the photobleaching constant at 630 nm which has previously been determined to be 14
J cm−2 (Valentine et al., 2011). λ is the wavelength (in nm) of the simulated photon
and µaPpIX is the absorption coefficient of PpIX at that wavelength. The photobleaching
8was considered within the MCRT code by introducing an iterative time dynamic where
5 × 106 photons were launched during each time step. At the end of each time step
the PpIX concentration was updated prior to launching a new set of photons. This
number of photons (5 × 106) was implemented to ensure that a good signal to noise
ratio was achieved within a reasonable simulation time. The number of time steps
varied depending on the light condition that was simulated since these corresponded to
different simulated treatment times. Since the majority of the interaction occurs at the
start of the treatment, the time steps were assumed to be shorter at the start of the
simulated treatment.
2.5. Different treatment modalities
During the occlusive treatment phase of conventional PDT the region of interest is
covered with an occlusive dressing. Before the light irradiation the dressing, and any
excess cream, is removed from the lesion. When daylight is used as the alternative light
source there is no occlusive dressing applied and any excess cream is left on the lesion
for the duration of the treatment. Since the amount of exposure will be different for
different patients during daylight PDT, for the work presented here it was assumed that
the occlusive treatment phase during daylight PDT was similar to conventional PDT.
The differences between the two treatment modalities that are simulated are
summarised in table 2. The most important difference is the continued accumulation and
production of PpIX during the light treatment for daylight PDT. While the production
of PpIX is assumed to be interrupted as the cream is removed prior to illumination
during conventional PDT. This is motivated by the short illumination time (15 minutes)
relative to the long occlusion (3 hours). These differences have to be considered when
determining the photobleaching discussed above. For each time iteration the initial
concentration in equation 11 has to be updated during daylight PDT since the PpIX is
assumed to continue to be produced. For this reason the concentration reduction due
to photobleaching as well as the concentration increase due to PpIX production have to
be considered during each time iteration.
Table 2: Description of the different treatment modalities where the PpIX is assumed to
continue to buildup during the light interaction phase of the treatment during daylight
PDT but not during conventional PDT. These properties are based on established
clinical practice (Morton et al., 2015).
Concept Conventional PDT Daylight PDT
Occlusive treatment, no light 3 hours 30 minutes
PpIX build up during illumination NO YES
Photobleaching during illumination YES YES
92.6. Light sources
In the MCRT model, the incident wavelengths are sampled such that the probability
distribution of the irradiance, and therefore the light spectra of the different light sources
are reproduced. The light spectra used to simulate both conventional PDT and daylight
PDT are shown in figure 2. The light source that is used to simulate conventional
PDT is the Aktilite and the total irradiance for this light source was assumed to be
82 mW cm−2. To simulate daylight PDT, both the direct and diffuse components are
included since this allows for different weather conditions to be simulated. For daylight
during clear conditions it was assumed that 80% of the total illumination was direct
daylight while 20% was diffuse daylight with a total irradiance of 41 mW cm−2. During
overcast condition the total illumination was assumed to contain 100% diffuse daylight
with a total irradiance of 8 mWc˙m−2.
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Figure 2: Figure showing the spectra included in the theoretical model. a) Light spectra
of both the direct and diffuse component of Daylight (Bird and Riordan, 1986). b) Light
spectrum of the Aktilite (Moseley, 2005), which is the typical light source simulated for
conventional PDT.
These different light conditions were used to simulate different PDT treatment
conditions. Our model was used to determine the photodynamic dose (PDD) for these
different treatment conditions where the PDD is defined as the number of absorbed
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photons, by the photosensitiser (PpIX), per unit volume (Farrell et al., 1998). Here
we adopt a toxic threshold as an approximation of the number of required absorption
events to achieve an effective treatment outcome. The value for the toxic threshold of
8.6×1017 photons cm−3 was adopted for illustrative purposes. This value has previously
been determined from measurements of Photofrin in liver tissue (Patterson et al., 1990).
3. Results
To demonstrate the build up of PpIX during the occlusive treatment phase (excluding
any light interaction) figure 3 shows the depth dependent concentration of PpIX after 30
min, 60 min and 180 min of occlusive treatment. The model successfully demonstrates
the increase in PpIX concentration with depth for prolonged incubation time.
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Figure 3: Figure showing the number density of PpIX molecules as a function of depth
as it builds up with time. Three different incubation times (30 min (solid), 1 hour
(dashed) and 3 hours (dotted)) are represented. This assumes no light interaction
during the production of PpIX. The incubation times are measured from the time of
drug application where an increased incubation time allows the concentration of PpIX
molecules to build up for longer.
As previously mentioned during the light interaction phase of conventional PDT,
it was assumed that there was no further production of PpIX. For this reason the
concentration of PpIX was assumed to only be affected by the concentration reduction
caused by photobleaching. However during daylight PDT the level of PpIX was not
only reduced due to photobleaching but the PpIX was also assumed to continue to be
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produced. The concentration of PpIX at different time points during illumination is
demonstrated in figure 4. The different time points are represented by light dose, where
the same light doses (10, 20, 40 and 75 J cm−2) are compared for the different light
conditions. The light dose is defined as the irradiance of the light source multiplied by
the total treatment time. Here the irradiance of daylight is defined over the wavelength
range 350 - 700 nm. Both daylight during clear and overcast conditions are represented
as well as the illumination by the Aktilite. For daylight PDT, PpIX is produced during
the light treatment which generated a different reduction compared to the conventional
PDT situation. Daylight PDT during overcast conditions resulted in overall larger
concentrations of PpIX within the tumour tissue compared to treatment during clear
conditions. This is due to the the prolonged treatment time required to deliver the total
light dose of 75 J cm−2 during overcast conditions, allowing more PpIX molecules to be
produced within the tumour tissue.
Figure 4: Representation of the change in the PpIX distribution during the light
treatment. Three different light conditions were compared where a) demonstrates
conventional PDT where the Aktilite was used as the illuminating light source assuming
an occlusion of 3 hours and an irradiance of 82 mW cm−2, b) demonstrates daylight PDT
during clear weather conditions (30 min of occlusion and irradiance of 41 mW cm−2)
and c) demonstrates daylight PDT during overcast conditions (30 min of occlusion and
irradiance of 8 mW cm−2).
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Figure 5 demonstrates the photodynamic dose for the three different treatment
conditions after a total delivered light dose corresponding to 75 J cm−2 (Valentine et al.,
2011). The photodynamic dose is defined as the number of absorbed photons per cubic
centimeter by the photosensitiser. This is a typical light dose delivered for conventional
PDT treatments and is therefore the treatment light dose that is compared. The figure
shows that the simulated treatment depth is not only dependent on the light penetration
but also on the depth dependent production of PpIX.
For daylight PDT during clear conditions different incubation times were explored.
Occlusive treatment phases of length 0 min, 30 min and 60 min were compared and the
results are shown in figure 6. By allowing the PpIX to build up for a longer period of
time prior to treatment, a deeper treatment is achieved.
4. Discussion
The different parameters associated with the PpIX production model such as the
different relaxation times, diffusion coefficient and initial concentrates, are vital to
accurately represent the distribution of PpIX within the tumour tissue. The values
used for the relaxation times agree with studies published by Star et al and Aalders et
al (Star et al., 2002; Aalders et al., 2001). Other studies suggest considerably different
values for the relaxation time. Salas Garcia et al suggested that τp = 84 ms and τap
= 24 h (Salas-Garc´ıa et al., 2012; Salas-Garc´ıa et al., 2014). These can be argued to
be unrealistic, especially since 84 ms is the non-radiative relaxation time of the PpIX
molecule (Jime´nez Pe´rez et al., 2008). Further studies are required to enable accurate
determination of the parameters adopted in this model.
For the adopted parameters, the resulting achieved effective treatment depth for
conventional PDT is comparable to those achieved when assuming an uniform initial
distribution of PpIX (Campbell et al., 2015). The results presented here (under the
stated assumptions) suggest that when simulating conventional PDT an uniform initial
distribution of PpIX is not an unreasonable assumption for the conditions presented
here. This will however strongly depend on the initial concentration and toxic threshold
that is assumed. When simulating daylight PDT the work presented here suggests
a larger dependence on the PpIX production. When assuming an initial uniform
distribution of PpIX, clear weather conditions indicates a deeper simulated treatment
compared to cloudy weather conditions. For the case presented here, assuming the same
light dose, the cloudy conditions indicates a deeper simulated treatment compared to the
clear conditions. This is explained by the prolonged treatment required during cloudy
conditions to reach the light dose of 75 J cm−2, which subsequently allows for additional
PpIX production.
The sensitivity of the parameters in equation 10 were explored by increasing and
decreasing their value in relation to the set of parameters adopted here. A reduced
and increased value of ε0M0
τap
results in a concentration profile of the PpIX that is scaled
linearly. For an adjusted τp, the concentration profile is not scaled linearly due to the
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Figure 5: Photodynamic dose (PDD) as a function of depth for conventional PDT
(Aktilie, solid) compared to daylight PDT during clear conditions (dashed) and overcast
conditions (dotted). The PDD after a total delivered light dose of 75 J cm−2 is
represented. The horizontal line corresponds to the toxic threshold which is an
approximation of the number of photons required to be absorbed by the PpIX to achieve
an effective treatment.
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Figure 6: Photodynamic dose (PDD) as a function of depth for three different initial
starting points after a total delivered light dose of 75 J cm−2 for daylight PDT (clear
conditions). The occlusive treatment times of 0 min (solid), 30 min (dotted) and 60 min
(dashed) are compared.The horizontal line corresponds to the toxic threshold.
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nature of equation 10. Hence a reduced τp has a lager effect on the PpIX distribution and
thereby the treatment depth compared to an increased taup. For example, if taup was
reduced by a factor of 100, the resulting treatment depth (assuming the toxic threshold
adopted here) would be reduced by approximately 0.5 mm. If taup was increased by
the same factor however, the resulting treatment depth would not be greatly affected.
A reduced diffusion coefficient results in slow and shallow distribution of PpIX and an
increased diffusion coefficient results in a more uniform distribution of PpIX due to the
faster diffusion of the prodrug. This consequently has the same effect on the effective
treatment depth. Adjusted parameters results in different concentration profiles of PpIX
which subsequently affects the effective treatment depth. Hence the treatment is not
only limited by light penetration but is also strongly affected by the distribution and
production of PpIX within the skin tissue.
The model presented here includes only the most important steps in the PpIX
production dynamic however there are clearly other aspects that could be considered
in future studies. These include the assumption that the PpIX did not diffuse from
the location where it is produced. It was also assumed that the location of the PpIX
within the cell did not change with time and thereby affect the treatment outcome.
Additionally it was also assumed that the concentration gradient of MAL molecules was
not affected by the production of PpIX or the photobleaching. It was also assumed that
the light penetration was not affected by the presence of the cream on the surface of the
lesion during daylight PDT. These, as well as the permeability of the cream through
skin tissue, are aspects of the models that for future developments should be considered.
The oxygen depletion during PDT was not considered and an unlimited oxygen supply
was assumed. It can be argued that the oxygen depletion during treatment will result
in a reduced production of PpIX. However, since the reduction of oxygen during PDT
is poorly understood, we have chosen to assume an unlimited supply.
The results from the study suggest that if PpIX is being produced during the full
daylight treatment, an extended treatment is to be recommended. A longer treatment,
during lower light intensities will allow deeper situated PpIX and therefore a possible
deeper treatment. However, when only considering superficial lesions (Fitzmaurice and
Eisen, 2016), a shorter treatment and thereby a more superficial effective treatment
could be sufficient for a successful result.
The diffusion model presented here is a major step forward towards a more accurate
representation of different treatment modalities. By adopting reasonable values for
the PpIX production parameters (C0, εp, τap, τp and D) the model indicates that the
treatment depth is not only limited by the penetration of light but also by the drug
diffusion and PpIX production rate. These are important factors to consider when
calculating and optimising PDT dosimetry. Our results highlight that when considering
daylight PDT is it important to consider these aspects of the treatment.
15
5. Conclusion
The incubation time associated with different treatment modalities results in different
initial distributions of the photosensitive molecule PpIX. A non-uniform distribution
of PpIX was investigated where a model was developed which depends on both the
distance from the surface as well as the time passed since prodrug application. The
results from the model suggest that treatment depths associated with PDT are not only
limited by the penetration of the light but also by the penetration of the prodrug as well
as the production of PpIX. Even though further investigation is required to establish
the distribution parameters, the work presented here is a significant step towards more
accurate theoretical predictions of PDT during different treatment conditions. Including
a time dependent PpIX production model is key in driving the theoretical simulation of
light based therapies forward.
Acknowledgments
C L Campbell acknowledges financial support from an UK EPSRC PhD studentship
(EP/K503162/1) and the Alfred Stewart Trust.
REFERENCES 16
References
Aalders, M. C. G., Van Der Vange, N., Star, W. M., and Sterenborg, H. J. C. M.
(2001). A mathematical evaluation of dose-dependent ppix fluorescence kinetics in
vivo. Photochemistry and Photobiology, 74(2):311–317.
Bird, R. and Riordan, C. (1986). Simple Solar Spectral Model for Direct and Diffuse
Irradiance on Horizontal and Tilted Planes at the Earth’s Surface for Cloudless
Atmospheres. Journal of Applied Meteorology, 25:87–97.
Campbell, C., Wood, K., Valentine, R., Brown, C., and Moseley, H. (2015). Monte
carlo modelling of daylight activated photodynamic therapy. Physics in medicine and
biology, 60(10):4059.
Casas, A., Fukuda, H., Di Venosa, G., and Del C.batlle, A. (2000). The influence of the
vehicle on the synthesis of porphyrins after topical application of 5-aminolaevulinic
acid. implications in cutaneous photodynamic sensitization. British Journal of
Dermatology, 143(3):564–572.
Castano, A., Demidova, T., and Hamblin, M. (2004). Mechanisms in photodynamic
therapy: part one - photosensitizers, photochemistry and cellular localization.
Photodiagnosis and Photodynamic Therapy, 1(4):279 – 293.
Crank, J. (1975). The mathematics of diffusion / by J. Crank. Clarendon Press Oxford
[England], 2nd ed. edition.
Donnelly, R. F., McCarron, P. A., and Woolfson, A. D. (2005). Drug delivery of
aminolevulinic acid from topical formulations intended for photodynamic therapy.
Photochemistry and Photobiology, 81(4):750–767.
Donnelly, R. F., McCarron, P. A., and Woolfson, A. D. (2007). Derivatives of 5-
aminolevulinic acid for photodynamic therapy. Perspectives in Medicinal Chemistry,
1:49–63.
Farrell, T., Hawkes, R., Patterson, M., and Wilson, B. (1998). Modeling of
photosensitizer fluorescence emission and photobleaching for photodynamic therapy
dosimetry. Appl. Opt., 37(31):7168–7183.
Fitzmaurice, S. and Eisen, D. B. (2016). Daylight photodynamic therapy: What is
known and what is yet to be determined. Dermatologic Surgery, 42(3):286–295.
Henyey, L. and Greenstein, J. (1941). Diffuse radiation in the Galaxy. , 93:70–83.
Jacques, S., Joseph, R., and Gofstein, G. (1993). How photobleaching affects dosimetry
and fluorescence monitoring of pdt in turbid media. Proc. SPIE, 1881:168–179.
Jime´nez Pe´rez, J. L., Cruz-Orea, A., Ramn-Gallegos, E., Gutierrez Fuentes, R., and
Sanchez Ramirez, J. F. (2008). Photoacoustic spectroscopy to determine in vitro the
non radiative relaxation time of protoporphyrin ix solution containing gold metallic
nanoparticles. The European Physical Journal Special Topics, 153(1):353–356.
Jongen, A. and Sterenborg, H. (1997). Mathematical description of photobleaching in
REFERENCES 17
vivo describing the influence of tissue optics on measured fluorescence signals. Physics
in Medicine and Biology, 42(9):1701.
Juzenas, P., Juzeniene, A., Iani, V., and Moan, J. (2009). Depth profile
of protoporphyrin ix fluorescence in an amelanotic mouse melanoma model.
Photochemistry and Photobiology, 85(3):760–764.
Malik, Z., Kostenich, G., Roitman, L., Ehrenberg, B., and Orenstein, A. (1995).
Topical application of 5-aminolevulinic acid, {DMSO} and edta: protoporphyrin
{IX} accumulation in skin and tumours of mice. Journal of Photochemistry and
Photobiology B: Biology, 28(3):213 – 218.
Morton, C., Wulf, H., Szeimies, R., Gilaberte, Y., Basset-Seguin, N., Sotiriou, E.,
Piaserico, S., Hunger, R., Baharlou, S., Sidoroff, A., et al. (2015). Practical approach
to the use of daylight photodynamic therapy with topical methyl aminolevulinate
for actinic keratosis: a european consensus. Journal of the European Academy of
Dermatology and Venereology.
Moseley, H. (2005). Light distribution and calibration of commercial pdt led arrays.
Photochem. Photobiol. Sci., 4:911–914.
Naghavi, N., Miranbaygi, M., and Sazgarnia, A. (2011). Simulation of fractionated
and continuous irradiation in photodynamic therapy: study the differences
between photobleaching and singlet oxygen dose deposition. Australasian Physical
Engineering Sciences in Medicine, 34(2):203–211.
Patterson, M. S., Wilson, B., and Graff, R. (1990). In vivo tests of the concept
of photodynamic threshold dose in normal rat liver photosensitized by aluminum
chlorosulphonated phthalocyanine. Photochemistry and Photobiology, 51(3):343–349.
Robinson, D., de Bruijn, H., van der Veen, N., Stringer, M., Brown, S., and Star,
W. (1998). Fluorescence photobleaching of ala-induced protoporphyrin ix during
photodynamic therapy of normal hairless mouse skin: the effect of light dose and
irradiance and the resulting biological effect. Photochem Photobiol, 67(1):140–9.
Salas-Garc´ıa, I., Fanjul-Ve´lez, F., and Arce-Diego, J. L. (2014). Superficial radially
resolved fluorescence and 3d photochemical time-dependent model for photodynamic
therapy. Opt. Lett., 39(7):1845–1848.
Salas-Garc´ıa, I., Fanjul-Vlez, F., and Arce-Diego, J. L. (2012). Photosensitizer
absorption coefficient modeling and necrosis prediction during photodynamic therapy.
Journal of Photochemistry and Photobiology B: Biology, 114(0):79 – 86.
Salomatina, E., Jiang, B., Novak, J., and Yaroslavsky, A. N. (2006). Optical properties
of normal and cancerous human skin in the visible and near-infrared spectral range.
Journal of Biomedical Optics, 11(6):064026–064026–9.
Star, W. M., Aalders, M. C. G., Sac, A., and Sterenborg, H. J. C. M.
(2002). Quantitative model calculation of the time-dependent protoporphyrin ix
concentration in normal human epidermis after delivery of ala by passive topical
application or iontophoresis. Photochemistry and Photobiology, 75(4):424–432.
REFERENCES 18
Svaasand, L. O., Wyss, P., Wyss, M.-T., Tadir, Y., Tromberg, B. J., and Berns, M. W.
(1996). Dosimetry model for photodynamic therapy with topically administered
photosensitizers. Lasers in Surgery and Medicine, 18(2):139–149.
Valentine, R., Brown, C., Moseley, H., Ibbotson, S., and Wood, K. (2011). Monte carlo
modeling of in vivo protoporphyrin ix fluorescence and singlet oxygen production
during photodynamic therapy for patients presenting with superficial basal cell
carcinomas. Journal of Biomedical Optics, 16(4):048002–048002–11.
van den Akker, J. T. H. M., Iani, V., Star, W. M., Sterenborg, H. J. C. M., and Moan, J.
(2000). Topical application of 5-aminolevulinic acid hexyl ester and 5-aminolevulinic
acid to normal nude mouse skin: Differences in protoporphyrin ix fluorescence kinetics
and the role of the stratum corneum. Photochemistry and Photobiology, 72(5):681–
689.
Van Gemert, M., Jacques, S., Sterenborg, H., and Star, W. M. (1989). Skin optics.
Biomedical Engineering, IEEE Transactions on, 36(12):1146–1154.
Wachowska, M., Muchowicz, A., Firczuk, M., Gabrysiak, M., Winiarska, M., Wanczyk,
M., Bojarczuk, K., and Golab, J. (2011). Aminolevulinic acid (ala) as a prodrug in
photodynamic therapy of cancer. Molecules, 16(5):4140–4164.
Wiegell, S., Hadersdal, M., Philipsen, P., Eriksen, P., Enk, C., and Wulf, H. (2008).
Continuous activation of ppix by daylight is as effective as and less painful than
conventional photodynamic therapy for actinic keratoses; a randomized, controlled,
single-blinded study. British Journal of Dermatology, 158(4):740–746.
Wiegell, S., Heydenreich, J., Fabricius, S., and Wulf, H. (2011). Continuous ultra-low-
intensity artificial daylight is not as effective as red led light in photodynamic therapy
of multiple actinic keratoses. Photodermatology, Photoimmunology Photomedicine,
27(6):280–285.
Wiegell, S., Skodt, V., and Wulf, H. (2013). Daylight-mediated photodynamic therapy
of basal cell carcinomas - an explorative study. Journal of the European Academy of
Dermatology and Venereology.
Wiegell, S., Wulf, H., Szeimies, R.-M., Basset-Seguin, N., Bissonnette, R., Gerritsen,
M.-J., Gilaberte, Y., Calzavara-Pinton, P., Morton, C., Sidoroff, A., and Braathen,
L. (2012). Daylight photodynamic therapy for actinic keratosis: an international
consensus. Journal of the European Academy of Dermatology and Venereology,
26(6):673–679.
Wilson, B. and Patterson, M. (2008). The physics, biophysics and technology of
photodynamic therapy. Physics in Medicine and Biology, 53(9):R61.
Wood, K. (2013). http://www-star.st-and.ac.uk/ kw25/. Monte Carlo Radiation
Transfer.
Wood, K. and R. J. Reynolds, R. (1999). A model for the scattered light contribution
and polarization of the diffuse h galactic background. The Astrophysical Journal,
525(2):799.
REFERENCES 19
Yudovsky, D. and Pilon, L. (2011). Retrieving skin properties from in vivo spectral
reflectance measurements. Journal of Biophotonics, 4(5):305–314.
